In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...

The High Court's ruling declared one of Moderna's mRNA technology patents invalid but upheld another, confirming that Pfizer and BioNTech SE's BNTX Comirnaty vaccine had infringed on it.

Moderna, along with rivals Pfizer and BioNTech, achieved an astonishing public health success by developing an mRNA vaccine to fight the COVID-19 pandemic in less than a year. The companies also ...

Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker ...

Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...

with BioNTech/Pfizer and Moderna continuing to dominate the market. BioNTech's mRNA pipeline, which requires expertise in the modality as well as bioinformatics, will be difficult to replicate by ...

The British pharma giant alleges that Moderna ignored patents relating to lipid nanoparticles used in mRNA vaccine formulation technology. It follows a similar lawsuit against Pfizer and BioNTech ...

In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on Moderna (MRNA – Research Report). The company’s shares closed yesterday at $50.28. Olson covers the Healthcare sector ...

Oct 16 (Reuters) - Moderna (MRNA.O), opens new tab was hit with a ... The lawsuit adds to a web of U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...